Golimumab, a human monoclonal antibody specific to TNF-α, was administrated to determine whether the anti-TNF-α antibody could preserve beta-cell function in young people with newly diagnosed overt T1D. The gene discussed is TNF; the disease is type 1 diabetes mellitus.